@doseresponse.bsky.social
Reposted
New study out today in Nature Comms: www.nature.com/articles/s41..., in which we set out to test whether ultrasound could influence the reward-related learning computations of the nucleus accumbens, building on decades of work on dopaminergic prediction error and reinforcement learning. And it did.
Non-invasive ultrasonic neuromodulation of the human nucleus accumbens impacts reward sensitivity - Nature Communications
This study shows that non-invasive ultrasound to the human nucleus accumbens can modulate deep brain activity and enhance reward-guided learning, offering a potential alternative to invasive neuromodu...
www.nature.com
November 28, 2025 at 12:26 PM
New study out today in Nature Comms: www.nature.com/articles/s41..., in which we set out to test whether ultrasound could influence the reward-related learning computations of the nucleus accumbens, building on decades of work on dopaminergic prediction error and reinforcement learning. And it did.
Reposted
My dissertation paper finally dropped in Nature Communications!
Overall, the conclusion is that psilocybin may be useful in reducing drug craving that often precipitates relapse through mechanisms related to 5-HT2A activation.
www.nature.com/articles/s41...
Overall, the conclusion is that psilocybin may be useful in reducing drug craving that often precipitates relapse through mechanisms related to 5-HT2A activation.
www.nature.com/articles/s41...
Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward - Nature Communications
Here Jaster et al., show a single psilocybin dose produce sex-specific post-acute changes in opioid reward and withdrawal via 5-HT2A receptors in frontal cortex-to–nucleus accumbens circuits, with epi...
www.nature.com
November 20, 2025 at 1:46 PM
My dissertation paper finally dropped in Nature Communications!
Overall, the conclusion is that psilocybin may be useful in reducing drug craving that often precipitates relapse through mechanisms related to 5-HT2A activation.
www.nature.com/articles/s41...
Overall, the conclusion is that psilocybin may be useful in reducing drug craving that often precipitates relapse through mechanisms related to 5-HT2A activation.
www.nature.com/articles/s41...
Reposted
🚨 New science alert! Our cross-species study, now in Nature Neuroscience, demonstrates psychedelics distort how we should interpret functional brain imaging.
👇🧵
nature.com/articles/s41...
#Neuroscience #Psychedelics #BrainImaging
👇🧵
nature.com/articles/s41...
#Neuroscience #Psychedelics #BrainImaging
Psychedelic 5-HT2A receptor agonism alters neurovascular coupling and differentially affects neuronal and hemodynamic measures of brain function
Nature Neuroscience - Padawer-Curry et al. show that the hallucinogenic 5-HT2A receptor agonist DOI alters neurovascular coupling in mice, with implications for the interpretation of human fMRI...
nature.com
October 15, 2025 at 8:18 PM
🚨 New science alert! Our cross-species study, now in Nature Neuroscience, demonstrates psychedelics distort how we should interpret functional brain imaging.
👇🧵
nature.com/articles/s41...
#Neuroscience #Psychedelics #BrainImaging
👇🧵
nature.com/articles/s41...
#Neuroscience #Psychedelics #BrainImaging
Reposted
New paper in Nature Neuro, with very impressive results (in mice):
Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain
www.nature.com/articles/s41...
Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain
www.nature.com/articles/s41...
Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain - Nature Neuroscience
Hammo et al. show that a single dose of psilocybin rapidly and sustainably relieves both chronic pain and anxiodepressive-like behaviors in mice by restoring prefrontal activity through partial agonism at 5-HT2A and 5-HT1A receptors.
www.nature.com
October 9, 2025 at 10:01 AM
New paper in Nature Neuro, with very impressive results (in mice):
Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain
www.nature.com/articles/s41...
Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain
www.nature.com/articles/s41...
Reposted
Considering the phase 2 LSD for anxiety study has been published and is in the news a bit right now, here's a piece from last year where I spoke to the CMO of MindMed about the trial's somewhat unique protocol. Bit more detail here about how the dose sessions worked than in the actual study.
Some psychedelic medicine developers want to ditch the therapy aspect. What could go wrong?
Are drugs like psilocybin and MDMA still safe and effective in the absence of psychotherapy?
www.salon.com
September 7, 2025 at 10:21 PM
Considering the phase 2 LSD for anxiety study has been published and is in the news a bit right now, here's a piece from last year where I spoke to the CMO of MindMed about the trial's somewhat unique protocol. Bit more detail here about how the dose sessions worked than in the actual study.
Neat- Spontaneous glutamate release activates mGluR signaling to drive rapid antidepressant responses www.pnas.org/doi/10.1073/...
Spontaneous glutamate release activates mGluR signaling to drive rapid antidepressant responses | PNAS
Major depressive disorder affects millions worldwide, yet current treatments require
prolonged administration. In contrast, ketamine produces rapid...
www.pnas.org
September 10, 2025 at 10:48 AM
Neat- Spontaneous glutamate release activates mGluR signaling to drive rapid antidepressant responses www.pnas.org/doi/10.1073/...
Reposted
Does #ketamine work via opioid system?
This controversial idea finds new support in a randomized trial, where the opioid blocker naltrexone impeded ketamine's #antidepressant and glutamatergic effects:
www.ncbi.nlm.nih.gov/pubmed/40707...
#depression #psychiatry #pmhnp
This controversial idea finds new support in a randomized trial, where the opioid blocker naltrexone impeded ketamine's #antidepressant and glutamatergic effects:
www.ncbi.nlm.nih.gov/pubmed/40707...
#depression #psychiatry #pmhnp
August 11, 2025 at 12:02 PM
Does #ketamine work via opioid system?
This controversial idea finds new support in a randomized trial, where the opioid blocker naltrexone impeded ketamine's #antidepressant and glutamatergic effects:
www.ncbi.nlm.nih.gov/pubmed/40707...
#depression #psychiatry #pmhnp
This controversial idea finds new support in a randomized trial, where the opioid blocker naltrexone impeded ketamine's #antidepressant and glutamatergic effects:
www.ncbi.nlm.nih.gov/pubmed/40707...
#depression #psychiatry #pmhnp
Reposted
Reposted
The emotional architecture of the psychedelic
brain: If you are interested in #psychedelics and #emotions, take a look at our new paper: authors.elsevier.com/sd/article/S.... With Flora Moujaes, @nathalierieser.bsky.social, Lydia Belinger, Marcus Herdener, & Zarmeen Zahid. Just published in TICS.
brain: If you are interested in #psychedelics and #emotions, take a look at our new paper: authors.elsevier.com/sd/article/S.... With Flora Moujaes, @nathalierieser.bsky.social, Lydia Belinger, Marcus Herdener, & Zarmeen Zahid. Just published in TICS.
ScienceDirect.com | Science, health and medical journals, full text articles and books.
authors.elsevier.com
August 19, 2025 at 7:27 AM
The emotional architecture of the psychedelic
brain: If you are interested in #psychedelics and #emotions, take a look at our new paper: authors.elsevier.com/sd/article/S.... With Flora Moujaes, @nathalierieser.bsky.social, Lydia Belinger, Marcus Herdener, & Zarmeen Zahid. Just published in TICS.
brain: If you are interested in #psychedelics and #emotions, take a look at our new paper: authors.elsevier.com/sd/article/S.... With Flora Moujaes, @nathalierieser.bsky.social, Lydia Belinger, Marcus Herdener, & Zarmeen Zahid. Just published in TICS.
Reposted
🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...
August 18, 2025 at 1:17 PM
🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...